April 19, 2014 10:58 AM ET


Company Overview of NextWave Pharmaceuticals, Inc.

Company Overview

NextWave Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) and attention deficit hyperactivity disorder (ADHD). Its product pipeline includes NWP06, a methylphenidate extended-release oral suspension that is in Phase III clinical stage for the treatment of ADHD; NWP09, which are methylphenidate extended-release chewable tablets that are in Phase I clinical stage for the treatment of ADHD; and NWP08, which are clonidine extended-release chewable tablets that are in Phase I clinical stage for the treatment of CNS. NextWave Pharmaceuticals, Inc. was formerly known as Children ...

20450 Stevens Creek Boulevard

Suite 150

Cupertino, CA 95014

United States

Founded in 2005





Key Executives for NextWave Pharmaceuticals, Inc.

Age: 55
Chief Financial Officer and Senior Vice President
Age: 58
Executive Vice President and President of OTC Business
Age: 57
Chief Business Officer and Senior Vice President
Age: 47
Vice President of Business Development
Compensation as of Fiscal Year 2013.

NextWave Pharmaceuticals, Inc. Key Developments

NextWave Pharmaceuticals, Inc. Receives FDA Approval of Quillivant XR(TM) for Once-Daily Treatment of ADHD

NextWave Pharmaceuticals announced FDA approval of Quillivant XR(TM) for extended-release oral suspension, CII. Quillivant XR is approved for the treatment of Attention Deficit Hyperactivity Disorder. Quillivant XR is the first once-daily, extended-release liquid methylphenidate available for patients with ADHD. The approval of Quillivant XR fills a void that has long existed in the treatment of ADHD. The efficacy of Quillivant XR was evaluated in a randomized, double-blind, placebo-controlled, crossover, multicenter, laboratory classroom study of 45 children with ADHD. There was an open-label dose optimization period with an initial 20mg dose of Quillivant XR once daily in the morning. The dose was titrated weekly in 10 or 20mg increments until an optimal dose or maximum dose of 60mg per day was reached. Patients then entered a two-week double-blind, crossover treatment of the individually optimized dose of Quillivant XR or placebo. At the end of each week, trained observers evaluated the attention and behavior of the patients in a laboratory classroom using the SKAMP rating scale. Quillivant XR significantly improved ADHD symptoms compared to placebo at the primary endpoint of four hours post-dose, and in a secondary analysis, showed significant improvement at every time point measured, from 45 minutes to 12 hours after dosing. Quillivant XR is expected to become available in pharmacies in January 2013. Quillivant XR was developed using Tris Pharma's patent protected drug delivery platform.

Similar Private Companies By Industry

Company Name Region
Galileo Pharmaceuticals, Inc. United States
T&L Pharmacies, Inc. United States
HNP Pharmaceuticals United States
IMMMU, Inc. United States
Ceva Holdings Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NextWave Pharmaceuticals, Inc., please visit www.nextwavepharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.